C-LECTA
OFB Projektentwicklung has started the first construction phase of the “BioSquare Leipzig” on a partial area of around 11,600 m² of the construction site 6a on the street “Alte Messe.” The symbolic groundbreaking ceremony on September 22, 2022, took place in the presence of Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig), Dr. Marc Struhalla (CEO of c-LEcta GmbH) and Dr. Christoph Wiechmann (Office Manager for Leipzig at OFB Projektentwicklung). The ceremony marks the start of a modern campus for biotechnology and the life sciences that comprises several buildings. The excavation of around 35,000 m³ of soil is scheduled to be completed by mid-November this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005032/en/
From left to right: Dr. Marc Struhalla (CEO of c-LEcta GmbH), Dr. Christoph Wiechmann (OFB Leipzig) and Thomas Dienberg (Mayor for Urban Development and Construction of the City of Leipzig).
As early as February 2022, a facade competition was held for the project with five architectural firms and a jury consisting of politicians, architects, scientists, the tenant c-LEcta and OFB. The Leipzig-based firm KLM Architekten und Ingenieure GmbH has now been commissioned as building planner for the first construction phase with the facade design.
Above ground, the first construction phase consists of two independent buildings with a total of around 18,500 m² of rental space. Five floors are planned for Building A, which will be used by the biotechnology company c-LEcta GmbH in the future and will have around 10,500 m² of above-ground rental space.
c-LEcta has been located at the “Alte Messe” site since the company was founded in 2004, and moved into its headquarters in the BioCube in 2012. The company has changed significantly since then: What began as a university spin-off with five employees has now evolved into a leading global player in industrial biotechnology. In 2021, c-LEcta worked with over 400 customers from more than 40 countries in the food and pharmaceutical industries, and once again significantly increased its sales compared to the previous year. Along with this, the number of employees has also developed rapidly over the years. Since 2018 alone, the number has doubled to 120 employees. Further growth in the workforce is also planned in the years ahead, so there will not be enough space available for the office and laboratory space in the current building.
The neighboring Building B in the direction of Prager Strasse comprises seven stories and thus offers a view over the old trade fair grounds after their completion. The slight offset of the second building will create a forecourt that provides an inviting access to building B with a good quality stay. Furthermore, a shared underground parking garage with around 110 parking spaces is being built.
Construction work on c-Lecta’s new corporate headquarters is scheduled for completion in the first half of 2025. In the second building of the first construction phase, another 8,000 m² of rental space is being created. With floor heights of four meters and modern construction grids, both buildings offer maximum flexibility in terms of use, so that both office space and laboratory space can be realized.
“The BioSquare project development underscores Leipzig’s importance as an innovation center for biotechnology and the life sciences. We want to keep innovative companies in these future industries at the location and attract new ones. Of course, we are particularly pleased that c-LEcta, a Leipzig success story, is moving into the first construction phase,” said the mayor and alderman for Urban Development and Construction of the City of Leipzig, Thomas Dienberg.
“The groundbreaking ceremony for our new headquarters in Leipzig is obviously a very special moment. In 2025, we will move into a high-tech building here with state-of-the-art workplaces and laboratories. This will not only secure sufficient space for further development in the long term, but at the same time provide a state-of-the-art design concept for our employees. Collaboration, concentrated work and regeneration go hand in hand. We are pleased to be able to continue our history at our home location,” emphasized Dr. Marc Struhalla, CEO of the tenant c-LEcta.
Dr. Christoph Wiechmann, head of OFB’s Leipzig office, is also quite pleased: “It is great to see that the excavators are now turning and the realization phase of BioSquare has begun. The ‘Alte Messe’ has made a name for itself as a location for innovative companies. On our campus, we offer research institutions and technology companies completely new development opportunities and perfect framework conditions.”
The project site is located within sight of the well-known double M of the Leipzig Mustermesse. The neighboring S-Bahn station “Völkerschlachtdenkmal” as well as several streetcar and bus lines offer very good public transport connections. The freeway ring road can also be reached in less than five minutes. Several innovative research institutions and companies such as the Fraunhofer IZI, the Max Planck Institute, Bio-City or the German Center for Integrative Biodiversity Research (iDiv) have settled at the “Alte Messe” location in recent years.
OFB: WE CONTINUE TO DEVELOP.
OFB Projektentwicklung GmbH has been in the real estate business for over 60 years. And is still as committed as on the first day. As a subsidiary of Landesbank Hessen-Thüringen and part of the Helaba Immobiliengruppe, high-quality and sustainable large-scale real estate is our focus. Project development, project management and real estate management are our passion.
At our headquarters in Frankfurt/Main and in our branches in Berlin, Erfurt, Munich, Düsseldorf and Leipzig, around 140 employees realize successful real estate projects throughout Germany. In doing so, we want to work harder than others – and therefore take the interaction of economic, ecological and social components into account as early as the planning stage of our projects. The goal: to develop our projects further, and ourselves as well.
About c-LEcta
c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. Product development is based on the proprietary enzyme technology platform ENESYZ® and is carried out both in-house and in close cooperation with industry partners worldwide. c-LEcta supplies its products to more than 400 customers in over 40 countries. c-LEcta currently employs more than 120 people at its headquarters in Leipzig.
c-LEcta is part of the Kerry Group. Kerry is the world’s leading taste and nutrition partner for the food, beverage and pharmaceutical markets. The company employs 22,000 people across over 150 locations and uses its broad range of ingredient solutions to innovate with its customers and create great tasting products, with improved nutrition and functionality, while ensuring a better impact for the planet.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005032/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile5.11.2025 07:00:00 CET | Press release
This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types1,2 Galderma’s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide3,4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocainefor augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also
The Estée Lauder Companies Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders5.11.2025 02:08:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces the pricing of the previously announced registered public offering (the “Offering”) of the Company’s Class A Common Stock, par value $.01 per share, by trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) at a price to the public of $90 per share. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Offering is expected to close on November 6, 2025, subject to the satisfaction of customary closing conditions. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of th
The Earthshot Prize and 500 Global Announce Strategic Partnership to Advance Climate Innovation in Emerging Markets5.11.2025 01:01:00 CET | Press release
500 Global and The Earthshot Prize are partnering on an investment strategy to identify, support and scale climate solutions across Emerging Markets.Supporting three themes at the intersection of climate impact and commercial viability: AgTech, Clean Tech, and Nature Tech.The strategy was announced at The Earthshot Prize Summit in Rio De Janeiro ahead of the 2025 Earthshot Prize Awards Night, targeting to roll out H1 of 2026. 500 Global, one of the world’s most active venture capital firms and The Earthshot Prize, the world’s most prestigious and impactful environmental award, are announcing today a new strategic partnership to accelerate climate innovation in Emerging Markets, as climate finance is more relevant than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104586243/en/ 500 Global intends to develop and implement an investment strategy designed to de-risk early-stage investments, unlocking private cap
Cooler Master Announces the QUBE 540 PC Case, a Compact Size with Unlimited Creativity4.11.2025 23:58:00 CET | Press release
Designed for Creators, Gamers, and DIY Builders Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the QUBE 540, a compact case for today. The QUBE 540 offers orientation flexibility, so you can build a vertical or horizontal system that fits your desk or shelf. Inside, a modular interior lets you tailor the layout to your components and airflow preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104224092/en/ The QUBE 540 (Stardust Iron) with 3D-printed additions holding headphones and keyboard. The QUBE 540 keeps the clean, geometric design language of the QUBE series while raising the bar on practical adaptability. It fits comfortably in limited spaces such as small apartments and dorm rooms, and it looks at home in creator studios and living areas. The case ships in two colors, Moonstone or Stardust Iron, giving users options that blend with modern setups and room aes
IFF Reports Third Quarter 2025 Results4.11.2025 23:12:00 CET | Press release
Reaffirms Full Year 2025 Financial Guidance IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Consolidated Summary: Management Commentary “Our third quarter results demonstrate continued execution in a tough operating environment,” said Erik Fyrwald, CEO of IFF. “Sales momentum in Scent and Taste remain solid, supported by strong new win contributions. This performance helped offset short-term pressures in Health and Biosciences - which we are addressing by strengthening our innovation and commercial capabilities - and a sales reduction in Food Ingredients as we focus on driving higher margins.” “Profitability in the quarter improved high-single digits year-over-year, with margin expansion driven predominantly by productivity. By maintaining a disciplined focus on operational excellence, we are driving sustained profitability while investing in IFF for long-term success.” “In a more challenging environment, we’re doing what we
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
